Secukinumab

DEA Class; Rx

Common Brand Names; Cosentyx

  • Interleukin Inhibitors; 
  • Monoclonal Antibodies

Subcutaneous IgG1 monoclonal antibody that inhibits interleukin-17A (IL-17A)
Used for plaque psoriasis, psoriatic arthritis, enthesitis-related arthritis, ankylosing spondylitis, and active non-radiographic axial spondyloarthritis
May increase risk for serious infection and may cause hypersensitivity reactions

Indicated for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Indicated for active psoriatic arthritis (PsA) in adults

Indicated for adults with active ankylosing spondylitis

Indicated for active non-radiographic axial spondylarthritis with objective signs of inflammation

Hypersensitivity

  • Infections (29%)
  • Diarrhea (4.1%)
  • Upper respiratory tract infection (2.5%)
  • Rhinitis (1.4%)
  • Oral herpes (1.3%)
  • Pharyngitis (1.2%)
  • Rhinorrhea (1.2%)
  • Infections (28.7%)
  • Nasopharyngitis (11.4%)

May increase risk of infections; caution when considering use in patients with chronic infection or a history of recurrent infection

In the postmarketing setting, serious and some fatal infections reported; instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur; if a patient develops a serious infection, monitor the patient closely and discontinue therapy until infection resolves

Evaluate patients for tuberculosis (TB) infection before initiating; do not administer with active TB; for latent TB, initiate anti-TB therapy prior to initiation of secukinumab in patients with a history of latent or active TB in whom an adequate course of treatment cannot be confirmed; monitor patients closely for signs and symptoms of active TB during and after treatment

May exacerbate Crohn disease

Anaphylaxis and cases of urticaria reported; if this occurs, discontinue secukinumab immediately and initiate anaphylaxis treatment

Caution if latex allergic; the removable cap on the Sensoready pen and prefilled syringe contains natural rubber

Use caution when prescribing drug to patients with inflammatory bowel disease; exacerbations, in some cases serious, reported in clinical trials in plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis

Limited available human data regarding use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes

Unknown if excreted in human milk or absorbed systemically after ingestion; data are unavailable regarding effects on breastfed children or milk production

Adults

150 mg/dose subcutaneously for non-radiographic axial spondyloarthritis and enthesitis-related arthritis; 300 mg/dose subcutaneously for all other indications.

Geriatric

150 mg/dose subcutaneously for non-radiographic axial spondyloarthritis and enthesitis-related arthritis; 300 mg/dose subcutaneously for all other indications.

Adolescents

weighing 50 kg or more: 150 mg/dose subcutaneously.
weighing less than 50 kg: 75 mg/dose subcutaneously.

Children

2 to 12 years weighing 50 kg or more: 150 mg/dose subcutaneously.
2 to 12 years weighing 15 to 49 kg: 75 mg/dose subcutaneously.
1 year or weighing less than 15 kg: Safety and efficacy have not been established.

Infants

Safety and efficacy have not been established.

Neonates

Safety and efficacy have not been established.

Secukinumab

lyophilized powder for reconstitution

  • 150mg/vial

solution for injection

  • 150mg/prefilled syringe
  • 150mg/Sensoready pen

About the Author

You may also like these

0